CAR-T cell production

Authors

  • Martín Bonamino Brazilian National Cancer Institute (INCA)
  • Raquel Melo Alves Paiva Hospital Israelita Albert Einstein
  • Juliana Preto de Godoy Hospital Israelita Albert Einstein
  • Andrea Tiemi Kondo Hospital Israelita Albert Einstein
  • Oswaldo Keith Okamoto Universidade de São Paulo
  • Lucila Nassif Kerbauy Hospital Israelita Albert Einstein

DOI:

https://doi.org/10.46765/2675-374X.2022v3n1p155

Keywords:

CAR-T cells, GMP manufacturing, viral vector, genetic modification

Abstract

Cell therapy with T cells expressing chimeric antigen receptor (CAR-T) is a type of immunotherapy that involves the manipulation and reprogramming of immune cells (T lymphocytes) in order to recognize and kill tumor cells. For use in patients, CAR-T cells must be manufcatured inside a GMP facility according to a established procedure. 

Downloads

Published

04/24/2022

How to Cite

Bonamino, M. ., Melo Alves Paiva, R., Preto de Godoy, J., Tiemi Kondo, A., Keith Okamoto, O., & Nassif Kerbauy, L. (2022). CAR-T cell production. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 3(1), 155. https://doi.org/10.46765/2675-374X.2022v3n1p155

Issue

Vol. 3 No. 1 (2022): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Section

Original article

License

Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.